New hope for Tough-to-Treat T-Cell lymphoma? pacritinib trial opens
NCT ID NCT04858256
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin assessments. This is an early-phase trial to check effectiveness and safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Duke Cancer Institute
RECRUITINGDurham, North Carolina, 27710, United States
-
Moffitt Cancer Center
NOT_YET_RECRUITINGTampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43202, United States
-
University of Michigan Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?
- Combination therapy aims to boost response in rare skin cancers
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer
- New pill shows promise for rare blood cancer in Late-Stage trial